These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 25197025

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A, Jadidi S, Sarkar N, DiMarchi R, Schmitt C.
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [Abstract] [Full Text] [Related]

  • 4. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.
    Kostic A, King TA, Yang F, Chan KC, Yancopoulos GD, Gromada J, Harp JB.
    Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
    Bergman A, Tan B, Somayaji VR, Calle RA, Kazierad DJ.
    Diabetes Res Clin Pract; 2017 Apr; 126():95-104. PubMed ID: 28237861
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A, Schmidt S, Madsbad S, Holst JJ, Nørgaard K.
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [Abstract] [Full Text] [Related]

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 13. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
    Zhi J, Zhai S.
    J Clin Pharmacol; 2016 Feb; 56(2):231-8. PubMed ID: 26183686
    [Abstract] [Full Text] [Related]

  • 14. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
    Morgan ES, Tai LJ, Pham NC, Overman JK, Watts LM, Smith A, Jung SW, Gajdošík M, Krššák M, Krebs M, Geary RS, Baker BF, Bhanot S.
    Diabetes Care; 2019 Apr; 42(4):585-593. PubMed ID: 30765435
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N, Cho SH, Kim J, Shin D, Seol E, Lee H, Lim KS, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2014 Jan 01; 36(1):101-14. PubMed ID: 24373998
    [Abstract] [Full Text] [Related]

  • 19. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
    Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B.
    Diabetes Obes Metab; 2011 May 01; 13(5):434-8. PubMed ID: 21251179
    [Abstract] [Full Text] [Related]

  • 20. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE.
    Diabetes Technol Ther; 2012 Mar 01; 14(3):218-24. PubMed ID: 22136324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.